


F15845

Cat. No.:	HY-19463A
CAS No.:	470454-73-0
Molecular Formula:	C ₂₀ H ₂₅ NO ₂ S ₂
Molecular Weight:	375.55
Target:	Sodium Channel
Pathway:	Membrane Transporter/Ion Channel
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	F 15845 is a highly effective persistent sodium current blocker. F 15845 also is a cardioprotective agent, has anti-ischemic activity and exerts short- and long-term cardioprotection after myocardial infarction. F 15845 can be used for the research of myocardium functional impairment ^[1] .								
In Vitro	<p>F 15845 (10 nM-10 μM) concentration-dependently reduces veratrine-induced diastolic contracture with an IC₅₀ value of 0.14 μM in isolated atria^[1].</p> <p>F 15845 (0.1-10 μM) preserves viability in isolated cardiomyocytes exposed to lysophosphatidylcholine (LPC)^[1].</p> <p>F 15845 (0.3 μM) significantly counteracts [Na⁺] increase during no-flow ischemia^[1].</p> <p>F 15845 (0.3 μM, 0-35 min) delays the reduction in [Na⁺], but marks and maintains upon reperfusion^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								
In Vivo	<p>F 15845 (i.v.; 5 mg/kg) exhibits remarkable cardioprotective properties in anesthetized rat^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Rat^[1]</td> </tr> <tr> <td>Dosage:</td> <td>2.5 mg/kg, 5 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>intravenously</td> </tr> <tr> <td>Result:</td> <td>Significantly reduced infarct size, decreased of troponin I levels and limited the long-term expansion of infarct size.</td> </tr> </table>	Animal Model:	Rat ^[1]	Dosage:	2.5 mg/kg, 5 mg/kg	Administration:	intravenously	Result:	Significantly reduced infarct size, decreased of troponin I levels and limited the long-term expansion of infarct size.
Animal Model:	Rat ^[1]								
Dosage:	2.5 mg/kg, 5 mg/kg								
Administration:	intravenously								
Result:	Significantly reduced infarct size, decreased of troponin I levels and limited the long-term expansion of infarct size.								

REFERENCES

[1]. Bruno Vié, et al. 3-(R)-[3-(2-methoxyphenylthio-2-(S)-methylpropyl)amino-3,4-dihydro-2H-1,5-benzoxathiepine bromhydrate (F 15845) prevents ischemia-induced heart remodeling by reduction of the intracellular Na⁺ overload. J Pharmacol Exp Ther. 2009 Sep;330(3):696-703.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA